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Abstract
Background: Hard core smokers have been studied in many countries but only a few trials have compared the
effectiveness of smoking cessation with other smokers. The objective of this study was to compare the frequencies
of success in smoking cessation between hard-core smokers and other smokers.
Methods: Data were collected in Clermont-Ferrand from the Emile Roux dispensary ‘Pneumology and Tobaccology
Centre’ between 1999 and 2009. Assistance with smoking cessation was proposed to 1367 patients but only 1296
patients were included: 219 HCS and 1077 other smokers. Smoking cessation was considered a success when
patients were abstinent 6 months after the beginning of cessation. The profiles of the two types of smokers were
compared using Chi square test and Student’s t test. Multivariate logistic regression was used to investigate the
association between the smoking cessation result and the type of smokers.
Results: HCS more frequently consumed other psychoactive substances (41.1 % vs 25.7 % for other smokers;
p < 0.001). Current depression was more frequent in HCS (46.6 % vs 34.8 % for other smokers; p = 0.001).
Smoking cessation was less frequent in HCS (45.2 % vs 56.5 % for other smokers ; p = 0.002). In multivariate
analysis, after controlling for other factors, the frequency of smoking cessation was not significantly associated
with the type of smokers (p = 0.47). After limiting to initial factors (present before the beginning of smoking
cessation), the frequency of smoking cessation was still not significantly associated with the type of smokers
(p = 0.78).
Conclusion: Smoking cessation is possible for hard core smokers, who should be treated as other types of
smokers taking into account other factors:the problem is how to encourage them to try to stop smoking.
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Background
Smoking is the leading cause of avoidable death in the
world [1]. According to the World Health Organisation
smoking kills five million people every year, that is to say
more than HIV, tuberculosis and malaria together [2]. In
France, smoking is the leading cause of premature death
(before 65 years of age).
Despite these figures, smokers still find it difficult to
stop smoking: 73 % of smokers wish to stop; 22 % try
and less than 5 % succeed without assistance [3]. It is
suggested [4] that smokers who are more resistant to
control smoking are less likely to quit. This hypothesis
states that with the declining prevalence and growing
social disapproval of smoking, smokers become increas-
ingly socially disadvantaged [4, 5]. Hardcore smoking
has become a major public health challenge for tobacco
control and cancer prevention [1, 6–8]. So-called «
Hard-core Smokers » (HCS) seem to be unaffected by
prevention campaigns and tax increases on tobacco
products: most of them have no intention, and never
have had, to stop smoking because they love smoking
and do not believe in its dangers [9–12]. Prevalence
rates of hard core smoking are influenced by the cri-
teria used to define the phenomenon and are affected
by the lack of standard definition [13]. HCS smoke
more than other smokers and therefore show more fre-
quently comorbidities associated with smoking [14]. It
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therefore seems important to better understand the be-
haviour and profile of HCS to optimize the therapeutic
strategy and the follow-up [9, 15]: HCS quickly begin to
smoke regularly, have a greater level of consumption,
and persist with their habit even though it makes them
ill [10]. They frequently show higher levels of nicotine
dependence [16–19]. They are more frequently men
than women, and have lower levels of education and in-
come, as they are often unemployed and live alone.
They rarely have medical or dental cares. In addition,
they do not admit their dependence on tobacco and fre-
quently consume other legal or illegal addictive sub-
stances [20]. The proportion of HCS among smokers
varies from 5 to 15 %, depending partly on the coun-
try [11, 20, 21].
The possibility of different strategies for smoking ces-
sation in HCS has not yet been investigated, even
though it is well-known that structured assistance gives
smokers a greater chance of success [22]. The objective
of the study was to compare the percentages of success
in smoking cessation between hard-core smokers and
other smokers.
Methods
We included all persons attending in Clermont-Ferrand
the Emile Roux dispensary ”Pneumology and Tobaccol-
ogy Centre” where assistance with smoking cessation was
proposed between 1st January 1999 and 31st December
2009 (1367 patients). These patients could be sent to
the centre by their primary care physician or encour-
aged to go there by their families. Smoking cessation
could also be initiated by personnel of the centre dur-
ing a visit to the dispensary for another health prob-
lem. The use of the information collected for this
study was declared to the National Commission for
Data Protection (CNIL n° 1873761) and our study ad-
hered to the tenets of the Declaration of Helsinki.
After exclusion for missing information about age,
daily consumption of cigarettes or previous attempts
to stop smoking, and for age less than 26 years, the
cohort included 1296 patients (94.8 % of the atten-
dants). A previous attempt to stop smoking was re-
corded (but the information about the date was not
complete).
Finally, 219 patients were HCS (according to the most
stringent definition in the literature [13, 20]: age 26 or
over, more than 15 cigarettes a day and no previous
attempt to stop smoking) and the remaining 1077
patients were other smokers.
The results of cessation were split into two categories
(failure and success), according to the patient’s declara-
tions and the measurement (6 months after the begin-
ning smoking cessation) of level of carbon monoxide in
exhaled air less of than 7 ppm.
The studied factors were:
– age, sex, number of pack years, consumption of
another psychoactive product, number of previous
cessation attempts, duration of the longest
temporary cessation of smoking, former major
depression, current depression, current anxiety,
heart, lung or Ear-Nose-Throat (ENT) diseases
involving smoking; Fagerström score, Richmond
test, Demaria and Grimaldi test, position
according to the Prochaska and Di Clemente
cycle (Pre-contemplation, Contemplation,
Preparation, Action and Maintenance);
– nicotine substitution, initial dose of nicotine in
the replacement therapy, duration of the nicotine
replacement therapy; treatment with serotonin
reuptake inhibitors and duration of treatment;
treatment with bupropion and duration of
treatment; treatment with varenicline and duration
of treatment (all durations counted in weeks);
daily consumption of cigarettes (when weaning
began), weight gain (kilograms) from the beginning of
withdrawal; perception of the assistance provided by
the medical team during the follow-up, and perceived
difficulty to stop smoking.Between-groups compari-
sons of distributions for categorical data (Richmond
tests, Prochaska and DiClemente) were done with the
Chi2 test, and Fisher’s exact test when there were not
too many data. Comparisons of means (number of
cigarettes; Fagerström, Demaria and Grimaldi scores;
nicotine dose and durations; weight gain after treat-
ment) were done with Student’s t test. Multivariate
logistic regression was used to investigate the associ-
ation between the smoking cessation result and the
type of smokers. The first model included, all vari-
ables that were found by unifactorial analysis signifi-
cantly associated (p < 0.10) with cessation, except for
“previous attempts at smoking cessation” and “num-
ber of cigarettes per day” (because they were used to
define the groups). The variable ‘age’ was introduced
in the model as a binary variable with a cut off at
45 years (overall age median). The second model kept
only the variables defined at the initial consultation
which were found by unifactorial analysis to be sig-
nificantly associated (p < 0.10) with cessation. The
data were analysed using R 2.10.1 software.
Results
A. Unifactorial analysis
HCS were significantly less frequent than
other smokers to stop smoking (Table 1). They
were also more frequent to consume other
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psychoactive substances, and to show current
depression.
The proportions for treatment with Varenicline
(over 75), and the proportions for Bupropion
(over 172), did not differ significantly between the
two groups (Table 1). Weight gain after withdrawal
was more frequent in other smokers than in
HCS (p = 0.004) (Table 2).
Means were significantly higher in HCS for daily
number of cigarettes (p < 0.001) and cigarette
pack-years (p = 0.002). The same was true for the
Fagerström index (p < 0.001) which was higher in
HCS.
The Richmond results depended significantly
on the group (p < 0.001): the high results (great
motivation to stop smoking) were less frequent in
HCS, who were therefore less motivated than
other smokers to stop smoking. The differences
for the Demaria and Grimaldi test were also
significant (p = 0.003): scores were highest in
the other smokers.
The initial dose of the nicotine substitute
(p < 0.001) and the duration of substitution
(p = 0.008) were higher in HCS. The differences
for the duration of treatment with bupropion
and serotonin reuptake inhibitors were not
significant.
The perceived difficulty to stop smoking was
significantly dependent on the group: it appeared
greater for HCS (p = 0.03).The assistance provided
by the medical team during the follow-up, as
perceived by the patient was not significantly
dependent on the group (p = 0.27) (but HCS
appeared to be more sensitive than other smokers
to the assistance).
The status of the Prochaska and Di Clemente cycle
depended significantly on the group (p < 0.001):
more HCS (23.7 %) than other smokers (15.2 %)
stay in the “pre-contemplation” level (decision to
stop smoking).
B. Multifactorial analysis
Multifactorial logistic regression analyses were
carried out to look for an association between
smoking group and smoking cessation, after
adjustment for the other variables. For both
models all variables were included in one step.
The variables treatment with serotonin reuptake
inhibitors, varenicline, or bupropion were excluded
from the models due to convergence problems
(too small number of patients taking these
drugs). The type of smoker was not significantly
associated with cessation of smoking whatever
the model used.
a) Model with all variables significant in unifactorial
analysis
Most of the patients treated with varenicline
or bupropion were not included in the
model because their data ‘duration of
nicotine substitution’ and ‘initial NS dose’
were missing.
Table 1 Proportions of the two sub-populations according to
the different binary variables
Binary variables Other smokers HCS P
Sex(proportion of men) 47.3 % 57.5 % 0,006
History of depression 34.4 % 34.7 % 0,92
Current depression 34.8 46.6 0,001
Current depression with
history of depression
19.7 % 26 % 0,03
Current anxiety 36.7 % 42 % 0,14
Previous attempt 98.4 % 0 % <0.001
Other psychoactive substance 25.7 % 41.1 % <0.001
Cardiac diseases, pulmonary
and ENT
50.6 % 55.3 % 0,21
Nicotine substitution 88.7 % 87.7 % 0,67
Smoking cessation Success 56.5 % 45.2 % 0,002
Treatment with serotonin
reuptake inhibitors
50.7 % 51.6 % 0,81
Treatment with varenicline 5.5 % 7.7 % 0,18
Treatment with bupropion 14 % 9.6 % 0,08
Age (proportion of 45 years
and under)
51.2 % 48.9 % 0.53
Table 2 Means of the two sub-populations according to the
different quantitative variables
Quantitative variables mean (SD) Other smokers HCS P
Age 45.6 (10.6) 45.9 (11.1) 0.73
Fagerström score 7.2 (2.1) 8 (1.7) <0.001
Daily consumption of cigarettes 24.2 (10.7) 28.1 (11.6) <0.001
Number of pack years 29.7 (18) 33.9 (19.7) 0.002
Number of previous cessation
attempts
2.8 (2.8) 0 (0) <0.001
Demaria and Grimaldi test 11.7 (3.1) 11 (3.1) 0.003
Initial dose of nicotine in the
replacement therapy
26.2 (12.1) 29.6 (14.1) <0.001
Duration of the nicotine
replacement therapy (weeks)
14.6 (15.6) 28.1 (17.5) 0.008
Duration of treatment with
serotonin reuptake inhibitors
(weeks)
6.7 (5.1) 7 (4.1) 0.7
Duration of treatment with
Bupropion (weeks)
3.1 (1.2) 3.5 (1.6) 0.12
Duration of treatment with
Varenicline (weeks)
5 (2) 5.3 (2) 0.6
Weight gain (kilograms) 4.1 (3.8) 3.9 (2.9) 0.52
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Consequently, there were 1049 patients
(out of 1296) included in the analysis (Table 3).
The variable “smoking group” was not
significant but smoking cessation (Table 3) was
less frequent in patients a) who used other
psychoactive substances, b) with heart-lung-
ENT diseases and c) with former depression;
it was more frequent in those with Prochaska
cycle = 4 (smoker ready to change), and in
those with assistance provided by the medical
team during the follow-up, as perceived by
the patient as very important. It was also more
frequent in those with a longer duration of
nicotine replacement. It was more frequent in
those with weight gain after withdrawal and
those with age over 45.
b) Model with only variables at inclusion found
significant in unifactorial analysis
Due to missing data, there were 1258
patients (out of 1296) included in the analysis
(Table 4).
The variable “smoking group” was not
significant in this model either, but smoking
cessation (Table 4) was less frequent in those
with a) use of other psychoactive substances, b)
heart, lung or ENT diseases and c) a higher
score in the Fagerström test.
It was more frequent in those with higher
scores at the Richmond test, the Demaria-
Grimaldi test and the Prochaska Cycle and
those with age over 45
Discussion
The unifactorial analysis showed that smoking cessation
was less frequent in HCS (45 %) than in other smokers
(56 %).
We think that the longer NRT in HCS may be ex-
plained by:
– weaning syndrome and/or craving are often intense;
they are factors of smoking cessation failure in the
short and medium term [9, 10].
– given this, the smoker received increased support, in
the form of prolonged NRT associated with
behavioral and cognitive support.
However, after adjustment for other factors impacting
cessation, this result was not confirmed.
The benefits of smoking cessation are well known, es-
pecially with regard to cardiovascular and respiratory co-
morbidities [23, 24]but the presence of a disease was
associated with lower frequency of smoking cessation.
The desire to stop seems to be reduced when the disease
is already present, which confirms reports by Scholte,
Kotseva and Gregor [25–27].
It is well known that anxiety and depression are more
frequent in smokers [28–30], and that quitting smoking
is associated with a reduction in depression, anxiety, and
Table 3 Model with all variables (present at the initial
consultation and/or at follow-up) significantly linked with
smoking cessation in unifactorial analysis (1049 patients)
ORa IC 95 % P
Smoking group 0.84 0.53–1.35 0.47
Former depression 0.54 0.37–0.8 0.002
Current depression 1.06 0.7–1.62 0.78
Current anxiety 0.87 0.6–1.28 0.48
Other psychoactive substance 0.41 0.27–0.62 <0.001
Cardiac, pulmonary and ENT diseases 0.56 0.38–0.83 0.003
Richmond test 0.04
Demaria and Grimaldi test 1.03 0.97–1.09 0.35
Prochaska Cycle 0.01
Fagerström test 0.93 0.84–1.02 0.12
The assistance provided by the
medical team during the follow-up,
as perceived by the patient
<0.001
Perceived difficulty in smoking
cessation
<0.001
Pack years 1 0.99–1.01 0.88
Initial dose for nicotine replacement
therapy
0.98 0.96–1 0.07
Duration of nicotine replacement
therapy
1.02 1.01–1.04 0.003
Weight gain (yes/no) 4.3 3.05–6.08 <0.001
Age (binary variable) 2.5 1.64–3.81 <0.001
All the variables present in the model are shown in this table
ORa adjusted OR
Table 4 Model with only variables at inclusion (present at the
initial consultation) significantly linked with smoking cessation
in unifactorial analysis (1258 patients)
ORa IC 95 % P
Smoking group 0.94 0.66–1.33 0.72
Former depression 0.77 0.58–1.03 0.08
Current depression 0.92 0.67–1.27 0.63
Current anxiety 0.81 0.61–1.09 0.16
Other psychoactive substance 0.53 0.39–0.71 <0.001
Cardiac pulmonary and ENT diseases 0.64 0.47–0.86 0.003
Richmond test <0.001
Prochaska cycle <0.001
Fagerström test 0.92 0.86–0.99 0.03
Pack years 1.01 0.99–1.02 0.25
Demaria and Grimaldi test 1.07 1.02–1.12 0.004
Age (binary variable) 2.11 1.53–2.90 <0.001
All the variables present in the model are shown in this table
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stress, with an improvement in psychological quality of
life and positive affects compared with continuing to
smoke [31]. The associations between smoking cessa-
tion, anxiety and depression have been thoroughly stud-
ied by, for example, Taylor [32], Brown [33], McClave
[34] and Zvolensky [35]. It is also known that former
and current depressions have an impact on the risk of
smoking relapse, when considered separately or together,
and even after adjusting for anxiety disorders [36]. One
interesting result of our study is that «former depres-
sion» stood out of “current depression” and “anxiety”,
which was not intuitive because the disease was not ne-
cessarily present at the time of the study. Anxiety and
current depression were no longer significant in multi-
variate analysis: this could be the result of an effective
management of these diseases, either by the use of anti-
depressants, anxiolytics or other treatments.
In the model with all variables (i.e. at entry and during
follow up) patients treated with varenicline or bupropion
were not taken into account because nicotine replace-
ment therapy (initial dosage and therapy duration) was
not indicated for them. This is important because these
treatments are now widely used. In contrast, the second
model (i.e. at entry) includes all patients (with nicotine
replacement therapy, varenicline or bupropion).
Finally, the principal criterion to distinguish between
the two groups of smokers was their desire to stop
smoking, as shown by the results of the Prochaska cycle
and the Richmond test (which were worse for HCS) and,
beyond that, their desire for access to care: by definition
HCS are less motivated to stop smoking and another
study showed that they were less likely to seek medical
care [20].
After the other factors in the study were taken into ac-
count, there was no significant difference between the
two groups of smokers for smoking cessation. We thus
showed that hardcore smokers are able to quit. This re-
sult is coherent with previous results. Thus, Clare [5]
showed that hardcore smoking declined among the high
socioeconomic status smokers in Australia from 2001 to
2010., and Lund showed that the relative frequency of
HCS in Norway declined in the period 1996–2009 from
30 to 23 % [37].
“The fact that clinicians, in our study, considered that
HCS should require more intensive care may partially
explain these results. We found that HCS required a
higher initial dose of nicotine in the replacement therapy
and longer nicotine replacement therapy. As a conse-
quence, in the framework of a randomized double blind
study, we might not have found the same results. How-
ever, we did not aim to conduct such a study; we wanted
to know if, in clinical practice, taking into account the
other main confounding issues, smoking cessation at-
tempts would be useful. We think that our study also
indicates that in an observational situation, where HCS
seems to be attentively followed by clinicians, the results
are promising.”
As the frequency of smoking cessation showed no
great difference between HCS and other smokers, pre-
vention campaigns should aim at promoting the cessa-
tion and access to care [14]. Moreover, among hard core
smokers, distinct profiles based on perceived pros and
cons of smoking exist [38]. Each profile might require a
different tobacco control approach [38]. Further gains in
smoking cessation must focus on understanding the
characteristics of 'hard-to-engage' populations [39].
Finally, HCS differ from other smokers as they have
never attempted to stop smoking, but once on the way
to cessation their chances of success are satisfactory
(45 % which is surprisingly good compared with 56 %
among other smokers), which underlines the importance
of treating HCS. Moreover, new strategies focused on
HCS, like smoking reduction then cessation, appear
effective to help hard core smokers to quit and reduce
smoking [39] which is one more argument for encour-
aging HCS to try to quit smoking.
Strengths and limitations
The strength of this study is to show that success is sat-
isfactory for HCS engaged in smoking cessation. Besides,
once other factors were taken into account, the fre-
quency of cessation in HCS did not differ from that in
other smokers: this is very important because it shows
that HCS have a reasonable chance to stop smoking.
They should therefore not be neglected by caregivers as
they are not doomed to remain smokers all their lives.
The question now is how to encourage them to begin a
process of cessation. Our result is a clear indication that
the other factors described in the study need to be taken
into account in the management of HCS, in particular
their motivation and the maturity of their decision to
stop, even if it means delaying the start of cessation to
obtain better motivation.
The main limitation of our study is that our sample of
HCS may be biased as they all consulted at a smoking
cessation center: our HCS could thus be more inclined
to stop smoking than those in the general population.
This possible bias is difficult to avoid if we want to study
smoking cessation in HCS. Another limitation is that
other definitions of HCS are possible such as “smoker
aged 26 or older, with at least 15 cigarettes a day, no
attempt to stop smoking in the previous year and un-
interrupted smoking for 5 years” [40]. This definition
would have made our HCS group larger and the other-
smoker group smaller, and the differences between the
two groups would have been smaller. Another limitation
is related to the choice of the initial dose of nicotine in
replacement therapy as the relevant variable. We chose
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to use the initial NRT dose as it was systematically re-
corded in the medical record. It would have been im-
portant to take into account the eventual dose of
nicotine susbtitution, but this was not systematically
available. In fact, this initial dose was very rarely
modified.
Given these results, further research is needed to know
how to encourage HCS to try to stop smoking. Other
studies would be useful to compare HCS with Heavy
Chronic Smokers, another kind of obstinate smokers, to
identify the aspects that distinguish these two popula-
tions on smoking cessation prognosis.
Conclusion
After adjustment for different factors, the chances of
success for HCS were not significantly different from
those for other smokers. This underlines the need to en-
courage HCS to make an attempt to stop smoking.
Smoking cessation centres have a part to play with
regard to HCS. The evolution of their motivation, or the
maturation of their decision, plays a key role.
As the HCS status is probably acquired progressively,
studies are needed to identify the pathways that lead a
smoker to HCS status, and peculiarly sociological pro-
files. Better knowledge of HCS would thus make it pos-
sible to establish specific prevention strategies for this
category of smokers. In the same way, once cessation
has been achieved, the phenomena that push the obstin-
ate smoker to smoke again need to be identified during
follow-up so as to establish strategies to eliminate smok-
ing relapse. Through prevention, it is essential to stop
the emergence of HCS to reduce its frequency among
smokers.
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